Is Damora Therapeutics, Inc. (DMRA) a Buy, Sell, or Hold?
Damora Therapeutics, Inc.
NASDAQ:DMRA
$30.99 USD
$2.99 (10.68%)
- Volume
- 0
- Average Volume
- 542.57K
- Market Capitalization
- $1.91B
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $38.33
- Year Low
- $2.45
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.48
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jennifer A. Jarrett |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DMRA |
| CUSIP | 36322Q206 |
| CIK | 0001800315 |
| Web | https://www.damoratx.com |
| Phone | 457 070 5210 |
| Currency | USD |
| Employees | 7 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 22.48 |
| Quick Ratio | 22.48 |
| Cash Ratio | 22.38 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -15.10 |
| Price / Cash Flow | -95.22 |
| Price / Book | 0.08 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $35.00 |
| Forecast Upside/Downside | -22.53% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-158.13 |
| Trailing P/E Ratio | -0.17 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-209.84M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -122.61% |
| Return on Assets | -43.91% |
Financials Score
| AltmanZ Score | 39.42 |
| Piotroski Score | 3.00 |
| Working Capital | 511.6M |
| Total Assets | 535.44M |
| Ebit | -235M |
| Market Cap | 1.72B |
| Total Liabilities | 25.18M |
Poll Results
About Damora Therapeutics, Inc. (NASDAQ:DMRA) Stock
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts. ...
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 16:01:00
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 08:00:00
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
2026-05-27 07:22:57
Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-12 16:05:00
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively – – Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms – – Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 – BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the quarter ended March 31, 2026, and recent corporate highlights. “We are pleased with our meaningful progress in advancing our mutant calreticulin (mutCALR)-targeted therapy pipeline, including three highly differentiated assets with distinct mechanisms that uniquely position Damora to drive innovation across all forms of mutCALR-driven disease,” said Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics.
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 08:00:00
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees. The inducement grants were approved by Damora's independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-04-23 04:24:47
Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
2026-04-20 13:00:39
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Frequently Asked Questions
-
What is the current Damora Therapeutics, Inc. (DMRA) stock price?
-
Damora Therapeutics, Inc.(NASDAQ:DMRA) stock price is $30.99 in the last trading session. During the trading session, DMRA stock reached the peak price of $38.325 while $2.45 was the lowest point it dropped to. The percentage change in DMRA stock occurred in the recent session was 10.68% while the dollar amount for the price change in DMRA stock was $2.99.
-
DMRA's industry and sector of operation?
-
The NASDAQ listed DMRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DMRA?
-
Becker Hewes | Chief Medical Officer
Sherwin Sattarzadeh | Chief Operating Officer
Brian Burkavage | Senior VP of Finance, Principal Financial & Accounting Officer
Hakon Leffler | Co-Founder
Tariq Sethi FRCP | Co-Founder -
How many employees does DMRA have?
-
Number of DMRA employees currently stands at 7. DMRA operates from 75 State Street, Waltham, MA 02109, US.
-
Link for DMRA official website?
-
Official Website of DMRA is: https://www.damoratx.com
-
How do I contact DMRA?
-
DMRA could be contacted at phone #457 070 5210 and can also be accessed through its website. DMRA operates from 75 State Street, Waltham, MA 02109, US.
-
How many shares of DMRA are traded daily?
-
The average number of DMRA shares traded daily for last 3 months was 542.57K.
-
What is the market cap of DMRA currently?
-
The market value of DMRA currently stands at $1.91B with its latest stock price at $30.99